Pharsight

Drugs that contain Ferric Maltol

1. Accrufer patents expiration

ACCRUFER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9802973 SHIELD TX Crystalline forms of ferric maltol
Oct, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248148 SHIELD TX Mono (iron hydroxypyrone) and combination (iron hydroxypyrone and GI inflammation inhibiting agents) compositions for anaemia or H. pylori infections
Mar, 2031

(6 years from now)

US10179120 SHIELD TX Dosage regimen of ferric trimaltol
Jan, 2035

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 25, 2024

NCE-1 date: 26 July, 2023

Market Authorisation Date: 25 July, 2019

Treatment: Method of treating iron deficiency

Dosage: CAPSULE;ORAL

More Information on Dosage

ACCRUFER family patents

Family Patents